Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system

Szodoray, Péter; Alex, Philip; Chappell-Woodward, C. M.; Madland, Tor Magne; Knowlton, Nicholas; Dozmorov, Igor; Zeher, Margit; Jarvis, James N.; Nakken, Britt; Brun, Johan G.; Centola, Michael

doi:10.1093/rheumatology/kel306

Cited by 92 publications

(73 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Abundant levels of MIP-1α have been found in patients with RA 9 ; however, reported levels of MIP-1α have not been higher in AS, but have been higher in PsA 6,10 . In our study, levels of MIP-1α were higher in AS and in RA.…”

Section: To the Editormentioning

confidence: 93%

See 1 more Smart Citation

Anti-Tumor Necrosis Factor Therapies Reduce Serum Macrophage Inflammatory Protein-1α in Ankylosing Spondylitis: Table 1.

Akbulut¹,

Koca²,

Özgen³

et al. 2010

J Rheumatol

View full text Add to dashboard Cite

Section: To the Editormentioning

confidence: 93%

“…In our study, MCP-1 levels in RA and AS patients were similar to levels in controls, suggesting that MCP-1 may not play a significant role in the pathogenesis of these diseases. The reported MCP-1 levels have not been higher in AS, psoriatic arthritis (PsA), or reactive arthritis [6][7][8] .…”

Section: To the Editormentioning

confidence: 99%

Anti-Tumor Necrosis Factor Therapies Reduce Serum Macrophage Inflammatory Protein-1α in Ankylosing Spondylitis: Table 1.

Akbulut¹,

Koca²,

Özgen³

et al. 2010

J Rheumatol

View full text Add to dashboard Cite

“…In order to assess whether a shift in the cytokine homeostasis exists in autoimmune conditions, fueling the predominance of pro-inflammatory cells vs. immunoregulatory T-cells, we have measured a broad spectrum of circulating cytokines in patients with various systemic autoimmune and rheumatic diseases [36][37][38][39][40][41]. The clinical picture and immunocompetent-cell distribution of pSS Primary Sjögren's syndrome (pSS) is a chronic, slowly progressive, systemic autoimmune disease that predominantly affecting middle-aged women, although it can be seen in people of all ages, including children [42].…”

Section: Th17 Cells and The Th17/treg Ratio In Systemic Autoimmune DImentioning

confidence: 99%

Cytokine Milieu in Undifferentiated Connective Tissue Disease: a Comprehensive Review

Nakken

Bodolay

Szodoray

2014

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

Undifferentiated connective tissue disease (UCTD) is a unique clinical entity, a potential forerunner of well-established systemic autoimmune/rheumatic diseases. UCTD is characterized by the presence of various clinical symptoms, as well as a diverse repertoire of autoantibodies, resembling systemic autoimmune diseases. Since approximately one-third of these patients consequently transform into a full-blown systemic autoimmune/rheumatic disease, it is of major importance to assess pathogenic factors leading to this progression. In view of the fact that the serological and clinical picture of UCTD and systemic autoimmune diseases are very similar, it is assumed that analogous pathogenic factors perpetuate both disease entities. In systemic autoimmune conditions a quantitative and qualitative impairment of regulatory T cells have been shown previously and in parallel a relative dominance of proinflammatory Th17 cells has been introduced. Moreover the imbalance between regulatory and Th17 cells plays a pivotal role in the initiation and propagation of UCTD. Additionally, we depict a cytokine imbalance, which give raise to a biased T-cell homeostasis from the UCTD phase throughout the fully developed systemic autoimmune disease stage. The levels of IL-6, IL-12, IL-17, IL-23 and IFN- were pathologically increased with a parallel reduction of IL-10. We believe that the assessment of Th17/Treg cell ratio, as well as the simultaneous quantitation of cytokines may give a useful diagnostic tool at the early UCTD stage to identify patients with a higher chance of consecutive disease progression towards serious systemic autoimmune diseases. Moreover, the early-targeted immunomodulating therapy in these patients may decelerate, or even stop this progression, before the development of serious autoimmune conditions with organ damage.

show abstract

“…5 Data suggest that IL-12 and IL-23 have an important role in the pathogenesis of PsA and other arthritides. 45,46 A multicenter, randomized, double-blind, placebocontrolled phase II trial evaluating the efficacy and safety of ustekinumab for PsA was recently published. 47 Although detailed description of this trial goes beyond the scope of this review, is crucial to highlight the overall study design and results.…”

Section: Phase II Data For Psoriatic Arthritismentioning

confidence: 99%

Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis

Krulig

Gordon

2010

View full text Add to dashboard Cite

Introduction: Psoriasis is a chronic inflammatory skin disease affecting approximately 2% to 3% of the population worldwide. Discoveries over the past 3 to 5 years have significantly altered our view of psoriasis as primarily a T-cell mediated condition. The most recent research has demonstrated the essential role of specific cytokines in the development of this complex disease, including TNF-α, interleukin-23 (IL-23), and potentially, IL-22. These are all part of a newly defined autoimmune pathway directed by specialized T cells called Th17 helper T cells. Ustekinumab is a fully human monoclonal antibody that targets IL-12 and IL-23, thus targeting both Th1 and Th17 arms of immunity. It has a promising efficacy and safety profile that not only represents a valuable treatment alternative, but also a continuation in our constantly evolving understanding of this disorder. Aims: To review the emerging evidence supporting the use of ustekinumab in the management of moderate to severe plaque psoriasis. Evidence review: There is clear evidence that ustekinumab is effective in the treatment of moderate to severe psoriasis. Phase III trials (PHOENIX 1 and 2) demonstrated a statistically significant difference between Psoriasis Area and Severity Index (PASI) 75 responses achieved by patients receiving ustekinumab, given as a 45 mg or 90 mg subcutaneous injection every 12 weeks, than their placebo counterparts. Treatment with this novel agent resulted in a rapid onset of action, with over 60% of treated patients attaining Physician's Global Assessment (PGA) scores of "cleared" or "minimal" by week 12. Quality of life assessments paralleled clinical improvements. Clinical potential: Ustekinumab is an effective and efficient therapeutic option for patients with moderate to severe psoriasis. Although further studies are required to establish ustekinumab's place in the therapy of psoriasis, with its convenient dosing schedule and rapid onset of action, this drug could provide a great addition to the current therapeutic armamentarium available for psoriatic patients.

show abstract

Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system

Abstract: Our findings suggest that these factors modulate PsA pathology and the articular involvement in a synergistic manner. Identifying factors could be used in the development of clinical diagnostic tests, which are valuable to guide evidence-based diagnosis and disease management of PsA.

Cited by 92 publications

References 33 publications

Anti-Tumor Necrosis Factor Therapies Reduce Serum Macrophage Inflammatory Protein-1α in Ankylosing Spondylitis: Table 1.

Anti-Tumor Necrosis Factor Therapies Reduce Serum Macrophage Inflammatory Protein-1α in Ankylosing Spondylitis: Table 1.

Cytokine Milieu in Undifferentiated Connective Tissue Disease: a Comprehensive Review

Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis

Contact Info

Product

Resources

About